Hinge Health, Inc.
HNGE
$104.82
+1.87%
Hinge Health, Inc. is a healthcare technology company that operates a digital platform for treating and preventing joint and muscle pain, using AI-powered motion tracking to help members manage chronic musculoskeletal (MSK) conditions while reducing costs for employer and health plan clients. The company is a pure-play digital MSK provider, positioning itself as a platform-style disruptor in a large, traditionally physical-therapy-dominated market, with a proprietary patient movement data set that management and bulls argue constitutes a durable competitive moat. The current investor narrative centers on the company's transition from a high-growth, cash-burning private-market story into a profitable public company, with recent headlines highlighting strong Q2 results, raised guidance, and 51% revenue growth alongside expanding profitability. Debate now hinges on whether that growth is already priced into the shares after a dramatic multi-month rally, and whether intensifying competition in digital health can erode Hinge Health's differentiation.…
HNGE
Hinge Health, Inc.
$104.82
Related headlines
Investment Opinion: Should I buy HNGE Today?
The synthesized recommendation is Hold, with a bias toward accumulating on pullbacks. The core thesis is that Hinge Health is a high-quality, rapidly growing digital health platform with a fortress balance sheet and expanding profitability, but the stock's 190.60% six-month rally has already priced in much of the near-term upside, as evidenced by the average analyst target of $110.56 implying only 7.4% upside and the consensus recommendation of 'buy' with a mean of 1.53. The risk/reward is balanced at current levels, favoring patience over aggressive buying.
Supporting evidence for the Hold rating includes: 1) exceptional revenue growth of 53% year-over-year in Q2 2026, with revenue reaching $212.82 million; 2) a profitability inflection with net income of $43.69 million (20.53% net margin) and gross margin of 86.44%, up from 70.28% in Q2 2025; 3) strong cash generation with trailing free cash flow of $287.33 million and a debt-to-equity of just 0.021; and 4) a premium valuation with a PS ratio of 6.26x and forward PE of 33.66x, which is above the sector average but potentially justified by growth. The implied upside to the average target is modest at 7.4%, and the stock trades at 99.6% of its 52-week range, suggesting limited near-term margin of safety.
The biggest risks that could invalidate the thesis are: 1) a deceleration in revenue growth below 30%, which would likely trigger a valuation reset; 2) intensifying competition in digital MSK that erodes Hinge Health's differentiation and pricing power; and 3) a broader market rotation away from high-multiple growth stocks, especially if interest rates remain elevated. The rating would upgrade to Buy if the stock pulls back to the $90-$95 support zone (implying a more attractive entry point) or if revenue growth accelerates above 60% with margin expansion. It would downgrade to Sell if revenue growth falls below 20% or if gross margins compress below 80%. Relative to its history, the stock is fairly valued on a forward PE basis (33.66x vs. historical range of 22.42x to 37.73x), but the PS ratio of 6.26x is well below its historical 30.73x, reflecting the massive revenue growth and profitability ramp. Overall, the stock appears fairly valued after its tremendous run, with the market pricing in continued strong execution.
Sign up to view all
HNGE 12-Month Price Forecast
Hinge Health is a high-quality growth story with exceptional revenue growth, expanding profitability, and a strong balance sheet, but the stock's massive rally has left it trading near its 52-week high with limited analyst upside. The neutral stance reflects a balance between the company's fundamental strength and the stock's extended valuation and technical position. The base case (55% probability) sees the stock trading in the $105-$115 range, aligned with the analyst average target, as growth moderates but remains robust. An upgrade to bullish would require a pullback to the $90-$95 support zone or evidence of accelerating growth and margin expansion; a downgrade to bearish would occur if revenue growth falls below 30% or if competitive pressures intensify. Given the risk/reward at current levels, investors may want to wait for a better entry point.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Hinge Health, Inc.'s 12-month outlook, with a consensus price target around $111.19 and implied upside of +6.1% versus the current price.
Average Target
$111.19
0 analysts
Implied Upside
+6.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$90 - $140
Analyst target range
Coverage is robust with 16 analysts, and sentiment is decisively bullish: the consensus recommendation is "buy" with a recommendation mean of 1.53 (where 1.0 is a strong buy), and the average target price of $110.56 implies roughly +7.4% upside from the current $102.90. The Buy/Hold/Sell distribution skews heavily toward Buy, with recent actions including Stifel reiterating Buy (September 8, 2026), Truist Securities reiterating Buy (August 11, 2026), and a cluster of Overweight/Outperform reiterations from Needham, Citizens, RBC Capital, Evercore ISI, Wells Fargo, and Barclays following Q2 earnings on August 5, 2026. The only neutral voice in the recent record is Baird, which maintained a Neutral rating on September 22, 2026 — consistent with the Zacks "hold" thesis that growth is already priced in.
The target range spans $90.00 to $140.00, a wide $50 spread that signals meaningful disagreement about the company's trajectory. The high target of $140 implies roughly 36% upside and would require sustained 50%+ revenue growth, continued margin expansion toward software-like levels, and possibly multiple expansion on the forward PE — essentially a best-case execution scenario. The low target of $90 sits about 12.5% below the current price and prices in decelerating growth, competitive pressure in digital MSK, or margin compression as the company invests more heavily in sales and marketing ($81.41 million in Q2 2026, up from $68.80 million in Q1). Notably, the average target of $110.56 is only modestly above the current price, suggesting analysts see the stock as fairly valued after its massive run, and the absence of any recent downgrades — with all actions being reiterations rather than initiations or changes — indicates stable conviction rather than fresh enthusiasm at these levels.
Bulls vs Bears: HNGE Investment Factors
The bull case currently has stronger evidence, anchored by accelerating 53% revenue growth, a decisive profitability inflection with 86.44% gross margins, and a fortress balance sheet with $287.33 million in trailing free cash flow. However, the bear case is not without merit: the stock trades at 99.6% of its 52-week range after a 190.60% six-month surge, and the average analyst target of $110.56 implies only 7.4% upside, suggesting the market has already priced in much of the good news. The single most important tension is whether Hinge Health can sustain its 50%+ growth rate and margin expansion in the face of intensifying digital health competition, or whether growth decelerates and triggers a valuation reset. If growth holds above 40% with continued margin expansion, the premium multiple is justified; if growth slips below 30%, the stock could face a sharp de-rating given its extended technical position.
Bullish
- Explosive revenue growth with acceleration: Q2 2026 revenue of $212.82 million grew 53% year-over-year, accelerating from the prior-year trajectory and marking a notable step-up from Q1 2026's $182.31 million. The sequential cadence from $154.21M to $170.73M to $182.31M to $212.82M demonstrates consistent double-digit expansion, implying durable adoption of digital MSK care.
- Profitability inflection with software-like margins: Q2 2026 net income was $43.69 million (20.53% net margin) on gross margin of 86.44%, a dramatic turnaround from the $575.65 million net loss in Q2 2025. Operating income of $40.44 million (19.00% operating margin) and EBITDA of $45.49 million confirm the profitability is operational, not accounting-driven.
- Fortress balance sheet and strong cash generation: Debt-to-equity is just 0.021, the current ratio is 1.47, and trailing twelve-month free cash flow is $287.33 million, with Q2 2026 FCF of $99.56 million. The company ended Q2 with $287.67 million in cash and is actively returning capital via $26.53 million in Q2 buybacks and $104.97 million in Q1 2026.
- Strong analyst consensus and price targets: Coverage from 16 analysts yields a consensus 'buy' rating with a recommendation mean of 1.53, and the average target price of $110.56 implies roughly +7.4% upside from the current $102.90. Recent reiterations from Stifel, Truist, Needham, Citizens, RBC, Evercore ISI, Wells Fargo, and Barclays underscore stable conviction.
Bearish
- Extreme overextension near 52-week high: At $102.90, the stock sits at roughly 99.6% of its 52-week range (low of $30.08, high of $103.28), leaving little margin of safety. The 190.60% six-month advance dwarfs the S&P 500's 14.59% gain, and the maximum drawdown of -48.03% over the past year is a stark reminder of the downside risk.
- Valuation premium demands flawless execution: The PS ratio of 6.26x and EV/Sales of 10.45x are at a premium to the broader healthcare information services sector, while the forward PE of 33.66x sits well above the sector's high-teens to low-20s range. This growth premium is defensible only if Hinge Health sustains 30%+ top-line expansion and continued margin expansion.
- Limited analyst upside suggests fair valuation: The average target price of $110.56 implies only +7.4% upside from the current price, and the low target of $90 sits about 12.5% below the current price. The wide $50 target spread ($90 to $140) signals meaningful disagreement about the company's trajectory, with Baird maintaining a Neutral rating.
- Intensifying competition in digital health: The Zacks 'hold' thesis explicitly cites fierce competition in digital health as a reason growth is already priced in. While Hinge Health's proprietary patient movement data is argued to be a moat, competitors could erode differentiation, especially as the company increases sales and marketing spend ($81.41 million in Q2 2026, up from $68.80 million in Q1).
HNGE Technical Analysis
Hinge Health is in a powerful, sustained uptrend: the stock has gained 104.33% over the past year and 125.86% year-to-date, and at a current price of $102.90 it sits at roughly 99.6% of its 52-week range (52-week low of $30.08, 52-week high of $103.28). That positioning near the absolute top of the annual range signals strong momentum but also meaningful overextension risk, particularly after a 190.60% six-month advance that dwarfs the S&P 500's 14.59% gain over the same period. The stock is effectively trading at all-time-high territory, which historically favors trend-following strategies but leaves little margin of safety for mean reversion.
Short-term momentum remains positive but is decelerating relative to the longer-term trend: the 1-month change is 12.69% and the 3-month change is 15.88%, both strong in absolute terms but far below the 190.60% six-month and 104.33% one-year figures, indicating the explosive phase of the rally has matured into a steadier grind higher. Relative strength versus SPY remains decisively bullish across every window — +10.57 points over 1 month, +12.75 over 3 months, +176.01 over 6 months, and +88.33 over 1 year — confirming persistent outperformance rather than a one-off spike. The most recent session added 5.0% on volume of 1,702,089 shares, a high-conviction move that pushed the stock to a fresh closing high of $102.90, though the 2.64 short ratio suggests bears are not yet capitulating en masse.
Key technical levels are well defined: immediate resistance sits at the 52-week high of $103.28, just 0.4% above the current price, and a decisive breakout above that level would likely trigger momentum-chasing flows and confirm the uptrend's continuation. Support is anchored at the 52-week low of $30.08, but more practically the $90-$95 zone (the September consolidation range) represents the first meaningful floor; a breakdown below $90 would signal a trend change and expose the stock to a deeper retracement. The maximum drawdown of -48.03% over the past year is a stark reminder that this name can halve despite its uptrend, and while beta is not provided, the stock's 190.60% six-month gain against SPY's 14.59% implies volatility multiples of the broader market — position sizing should reflect that a 1.5x-2x beta equivalent is likely conservative for this profile.
Beta
—
—
Max Drawdown
-48.0%
Largest decline past year
52-Week Range
$30-$105
Price range past year
Annual Return
+110.5%
Cumulative gain past year
| Period | HNGE Return | S&P 500 |
|---|---|---|
| 1m | +18.3% | +1.8% |
| 3m | +17.4% | +3.5% |
| 6m | +152.8% | +11.2% |
| 1y | +110.5% | +19.1% |
| ytd | +130.1% | +14.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
HNGE Fundamental Analysis
Revenue growth is exceptional and, importantly, accelerating: Q2 2026 revenue of $212.82 million grew 53% year-over-year, up from $182.31 million in Q1 2026, $170.73 million in Q4 2025, and $139.10 million in Q2 2025. The sequential cadence — $154.21M (Q3 2025) to $170.73M to $182.31M to $212.82M — shows consistent double-digit sequential expansion with a notable step-up in the most recent quarter, and the 53% YoY rate compares favorably to the prior-year trajectory. With only one reportable segment, the entire platform is firing; the growth trend implies the investment case rests on durable adoption of digital MSK care by employers and payers rather than on a single product line.
Profitability has inflected decisively: Q2 2026 net income was $43.69 million (a 20.53% net margin) on gross profit of $183.95 million, a gross margin of 86.44% that expanded from 84.60% in Q1 2026 and 84.45% in Q4 2025. This marks a dramatic turnaround from Q2 2025, when the company posted a net loss of $575.65 million (driven largely by $590.98 million of stock-based compensation tied to its May 2025 IPO) and a 70.28% gross margin. Operating income of $40.44 million (19.00% operating margin) and EBITDA of $45.49 million confirm the profitability is operational, not accounting-driven, and the 86%+ gross margin is characteristic of a high-quality software-like healthcare platform rather than a services business.
Balance sheet and cash generation are fortress-like: debt-to-equity is just 0.021, the current ratio is 1.47, and trailing twelve-month free cash flow is $287.33 million, with Q2 2026 FCF of $99.56 million on operating cash flow of $101.41 million. The company ended Q2 with $287.67 million in cash and is actively returning capital — $26.53 million of stock repurchased in Q2 and $104.97 million in Q1 2026 — while still growing headcount and R&D ($34.06 million in Q2). ROE of -1.40 and ROA of 0.077 reflect the distorting effect of the IPO-related equity and SBC charges, but the underlying cash engine (FCF conversion of 98.17% of operating cash flow) means Hinge Health funds its own growth internally with no external financing dependence.
Quarterly Revenue
$212817000.0B
2026-06
Revenue YoY Growth
+53.0%
YoY Comparison
Gross Margin
86.4%
Latest Quarter
Free Cash Flow
$287327000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is HNGE Overvalued?
Because trailing net income is negative (trailing EPS of -$0.14, trailing PE of -8.67), the PE ratio is not meaningful as a primary metric; instead, the PS ratio of 6.26x is the appropriate lead valuation gauge, supported by the forward PE of 33.66x, which reflects the market's expectation that the company's rapid profitability ramp will normalize earnings. The gap between the negative trailing PE and the 33.66x forward PE, alongside a PEG ratio of essentially zero (-0.0025), signals that the market is pricing in explosive earnings growth — analyst estimated EPS of $5.29 versus the current loss — and that valuation is being underwritten on future earnings power rather than current profits.
Relative to the broader healthcare information services sector, the 6.26x PS ratio and 10.45x EV/Sales sit at a premium, though the comparison is complicated by the company's 53% revenue growth and 86% gross margin, which are well above typical sector norms. The forward PE of 33.66x against a sector that generally trades in the high-teens to low-20s multiple range implies a growth premium that is defensible only if Hinge Health sustains 30%+ top-line expansion and continued margin expansion. The PB ratio of 9.72x and price-to-free-cash-flow of 21.46x further underscore that investors are paying up for a capital-light, cash-generative platform.
Historically, the stock's own valuation band has compressed dramatically: PS ratio was 30.73x in Q2 2026's reported historical ratios, 16.63x in Q1 2026, and 21.64x in Q4 2025, versus the current 6.26x — a massive de-rating driven by the stock's price appreciation being outpaced by revenue growth and the shift to profitability. The forward PE of 33.66x versus historical PE readings of 37.73x (Q2 2026) and 22.42x (Q1 2026) places the current multiple in the middle of its short public history, suggesting the market is neither euphoric nor pessimistic on earnings-based valuation even as the price sits at 52-week highs. This combination — record price, compressed PS, mid-range forward PE — argues the rally has been fundamentally justified by earnings delivery rather than pure multiple expansion.
PE
-8.7x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 6x~38x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-6.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are relatively contained but not negligible. The company's debt-to-equity of 0.021 and current ratio of 1.47 indicate a healthy balance sheet, and trailing free cash flow of $287.33 million provides ample liquidity. However, the business is entirely dependent on continued adoption of digital MSK care by employers and payers, and a single reportable segment means there is no diversification buffer. Additionally, the company's profitability is recent; Q2 2025 posted a net loss of $575.65 million due to $590.98 million in stock-based compensation tied to its May 2025 IPO, and while Q2 2026 net income was $43.69 million, the sustainability of this margin profile depends on maintaining high gross margins (86.44%) and managing sales and marketing spend, which rose to $81.41 million in Q2 2026 from $68.80 million in Q1.
Market and competitive risks are significant given the stock's extreme valuation and momentum. The PS ratio of 6.26x and forward PE of 33.66x represent a premium to the healthcare information services sector, leaving the stock vulnerable to multiple compression if growth decelerates or if interest rates remain elevated. The digital MSK space is becoming increasingly crowded, and while Hinge Health's AI-powered motion tracking and proprietary patient movement data are differentiators, competitors could erode its moat. The stock's beta is not provided, but its 190.60% six-month gain against SPY's 14.59% implies volatility multiples of the broader market, and the 2.64 short ratio suggests bears are not yet capitulating. Recent news from Zacks highlights that growth is already priced in and competition remains fierce, which could cap upside.
The worst-case scenario would involve a combination of decelerating revenue growth, margin compression, and a broader market rotation out of high-multiple growth stocks. If revenue growth slows to 20-30% and the forward PE compresses to the sector average of high-teens, the stock could retest its 52-week low of $30.08, representing a decline of approximately 70.8% from the current price of $102.90. Even a more moderate bear case, aligned with the analyst low target of $90, implies a 12.5% downside. The maximum drawdown of -48.03% over the past year shows that this stock can halve in adverse conditions, and investors should be prepared for significant volatility given the lack of a dividend and the stock's speculative growth profile.
FAQ
The key risks for HNGE, ranked by severity, are: 1) Growth deceleration risk: if revenue growth falls below 30%, the premium valuation (forward PE of 33.66x) could compress sharply, potentially sending the stock toward the analyst low target of $90 or lower. 2) Competitive risk: the digital MSK space is becoming increasingly crowded, and while Hinge Health's AI-powered motion tracking and proprietary patient movement data are differentiators, competitors could erode its moat and pricing power. 3) Valuation and momentum risk: the stock trades at 99.6% of its 52-week range after a 190.60% six-month surge, leaving little margin of safety and exposing it to profit-taking. 4) Macro risk: a broader market rotation out of high-multiple growth stocks, especially if interest rates remain elevated, could disproportionately impact HNGE given its high volatility (maximum drawdown of -48.03% over the past year).
The 12-month forecast for HNGE includes three scenarios: a base case (55% probability) with a target range of $105-$115, aligned with the analyst average target of $110.56, assuming revenue growth moderates to 35-45% and margins hold in the high teens; a bull case (25% probability) with a target range of $130-$140, requiring sustained 50%+ growth and margin expansion; and a bear case (20% probability) with a target range of $80-$90, assuming growth decelerates to 20-30% and competitive pressures intensify. The most likely scenario is the base case, where the stock trades sideways to modestly higher as the company delivers steady results but faces increasing competition. The key assumption behind the base case is that Hinge Health maintains its growth trajectory without significant multiple expansion or contraction.
HNGE appears fairly valued to slightly overvalued after its massive run. The PS ratio of 6.26x and EV/Sales of 10.45x are at a premium to the healthcare information services sector, while the forward PE of 33.66x is above the sector's high-teens to low-20s range. However, the premium is supported by 53% revenue growth and 86.44% gross margins, which are well above sector norms. Relative to its own history, the PS ratio has compressed dramatically from 30.73x in Q2 2026 to 6.26x, while the forward PE of 33.66x sits in the middle of its short public range (22.42x to 37.73x). The market is pricing in continued strong execution, and the average analyst target of $110.56 implies only 7.4% upside, suggesting the stock is fully valued in the near term.
HNGE presents a compelling growth story with 53% revenue growth, a profitability inflection, and a fortress balance sheet, but the stock's 190.60% six-month rally has left it trading at 99.6% of its 52-week range with only 7.4% upside to the average analyst target of $110.56. The risk/reward is balanced at current levels, making it a 'Hold' rather than an aggressive 'Buy'. For investors with a long-term horizon and tolerance for volatility, accumulating on pullbacks to the $90-$95 support zone could offer a more attractive entry point. The biggest downside risk is a growth deceleration that triggers a valuation reset, potentially sending the stock toward its 52-week low of $30.08 in a worst-case scenario. Overall, it is a good buy for growth-oriented investors who can stomach drawdowns and are willing to wait for a better price.
HNGE is more suitable for long-term investment (minimum 2-3 years) given its early growth stage, high volatility, and lack of dividend. The company is still in the early innings of penetrating the large digital MSK market, and its profitability inflection is recent, so earnings visibility is limited. The stock's beta is not provided, but its 190.60% six-month gain against SPY's 14.59% implies volatility multiples of the broader market, making it unsuitable for short-term traders with low risk tolerance. For long-term investors, the core thesis is that Hinge Health can sustain 30%+ revenue growth and expand margins, justifying a premium valuation over time. A suggested minimum holding period of 2-3 years allows the company to execute on its growth strategy and for the market to recognize its earnings power.